VivoSense is a technology company.
VivoSense has raised $25.0M across 1 funding round.
VivoSense has raised $25.0M in total across 1 funding round.
VivoSense has raised $25.0M in total across 1 funding round.
VivoSense's investors include Perceptive Advisors.
VivoSense is a healthcare software company founded in 2010 that specializes in analyzing wearable sensor data to develop regulatory-compliant digital biomarkers for pharmaceutical clinical trials.[1][2] Its proprietary VivoSense® platform processes real-world data from wearables to measure subtle physiological changes, enabling precise endpoints in trials for conditions like cancer, Alzheimer's, and rare diseases, serving clinical researchers, pharma companies, and healthcare researchers.[1][2][4] The company solves the challenge of interpreting complex sensor data into actionable, FDA-submissible clinical measures, accelerating patient-focused drug development and precision medicine; it raised $25M in Series A funding to expand this capability and has achieved growth through partnerships with top-10 pharma firms in open-label trials.[1][2]
With around 46-51 employees and $10.7M in revenue, VivoSense positions itself as the world leader in wearable sensor data analytics for clinical trials, offering end-to-end services from data collection to validated biomarkers.[1][2][4]
VivoSense was established in 2010 in Newport Coast, California, initially focusing on helping clinical researchers analyze and interpret wearable sensor data to enhance patient research and care.[1][2] While specific founders are not detailed in available sources, the company emerged amid rising interest in digital health technologies, innovating by creating novel digital biomarkers from wearables— a first in the industry for use as primary and secondary endpoints in regulated international pharma trials.[1][2]
Early traction came from addressing gaps in pharmaceutical clinical trials, particularly for rare diseases, with several studies advancing to open-label phases at major pharma companies; this built momentum, culminating in a $25M Series A financing round to scale wearable data collection and biomarker development.[1]
VivoSense rides the wave of digital biomarkers and wearable tech integration in clinical trials, capitalizing on post-2020 surges in remote monitoring accelerated by the pandemic.[1][2] Timing aligns with pharma's shift to real-world evidence (RWE) and precision medicine, where wearables generate vast datasets needing specialized analytics to meet regulatory standards like FDA's digital health guidelines.[1][4]
Market forces favoring VivoSense include exploding wearable adoption (e.g., smartwatches tracking gait, sleep), regulatory pushes for objective endpoints over subjective scales, and Big Pharma's $100B+ annual R&D spend seeking trial efficiency; it influences the ecosystem by standardizing sensor data for trials, enabling faster drug approvals in underserved areas like rare diseases.[1][2]
VivoSense is poised to expand its $25M-funded platform amid growing demand for AI-enhanced biomarker discovery, potentially powering more Phase III trials and consumer wellness applications.[1][2] Trends like multimodal wearables, AI data fusion, and global RWE mandates will shape its path, with influence evolving toward ecosystem leadership via pharma partnerships and possible acquisitions by larger CROs or tech-health giants. As wearable data scales, VivoSense's validated approach positions it to transform trials from Newport Coast's innovation hub.
VivoSense has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $25.0M Series A | Perceptive Advisors |